RSV vaccine uptake among Medicare Advantage enrollees: August 2023 to December 2024 Authors: Vishal Saundankar, Reiko Sato, Robyn Moucka, Pamela Smith, Kimbal Ford, Edward W Casey, Chris Barger, Richard Sheer, Brandon Suehs Published: 2026 ABSTRACT ABSTRACTRespiratory syncytial virus (RSV) is one of the most common causes of respiratory tract infections, disproportionately affecting young children, older adults, and those with chronic medical conditions. In the US, RSV vaccine recommendations by the US Centers for Disease Control (CDC) for adults were first issued in 2023 and have since evolved. Uptake of the RSV vaccine by eligible US adults has been slower than expected, with approximately one-fifth (21.0%) of adults aged ≥ 65 years enrolled in Medicare fee-for-service plans receiving the vaccine in the first season of availability. We analyzed RSV vaccine uptake over two seasons among older adults enrolled in Medicare Advantage. Overall RSV vaccine uptake was higher in the 2023/2024 season compared with the 2024/2025 season, peaking in October of both years. Adults ≥ 75 years had higher vaccine uptake than those 65–74 years. Vaccination was highest among groups at increased risk for severe RSV illness. Among approximately 1.7 MM individuals who met the 2024 CDC recommendations for vaccination, roughly 80% did not have evidence of RSV vaccination. Targeted strategies are needed to further reach adults who are at increased risk for severe RSV illness.KEYWORDS: Respiratory syncytial virus, Medicare Advantage, vaccination, respiratory tract infections, uptake, RSV vaccine Introduction Respiratory syncytial virus (RSV) infection is increasingly recognized as a common cause of acute respiratory illness in older adults and emerges seasonally, with peaks during the winter months in temperate regions.1–4 This virus is associated with high reinfection rates and can lead to more serious manifestations such as pneumonia and bronchiolitis.1,5,6 Risk factors for developing severe RSV illness in adults include advanced age (75 years or older), chronic heart or lung disease, a weakened immune system, residence in a nursing home or long-term care facility, and certain other underlying medical conditions such as diabetes mellitus, chronic liver disease, and a body mass index ≥40 among others.7,8 RSV can be associated with acute respiratory illness that requires medical attention, hospitalization, and can result in death. RSV can sometimes also lead to exacerbation of serious conditions such as asthma, chronic obstructive pulmonary disease, and heart failure.8,9 In adults aged ≥65 years in the United States, over 225,000 hospitalizations and 19,000 deaths are estimated to be due to RSV annually.10 The economic burden associated with RSV in US adults is equally staggering, with an estimated total direct cost of $15.2 billion and indirect costs of $9.7 billion, of which 63% and 36%, respectively, are in adults aged ≥60 years.10 The cost of RSV hospitalization is similar to that of influenza hospitalization, with a mean length of stay of 7–8 days.11,12 Recent evidence also suggests that the RSV‑associated costs are not limited to the acute phase of illness, but continue to impact the healthcare system beyond hospital discharge.12–14 In fact, patients aged 65 or more diagnosed with RSV have been reported to have more than twice as many emergency department (ED) visits over a 12‑month period as younger patients aged 18–64.15 In a real-world study among Medicare enrollees, almost half of the patients post-RSV infection had one or more RSV-related complications within a month.16 Since May 2023, the Food and Drug Administration (FDA) has approved three vaccines for the prevention of lower respiratory tract disease caused by RSV.17 In June 2023, the Centers for Disease Control and Prevention (CDC) recommended a single dose of RSV vaccine for adults aged 60 y or older, using a shared clinical decision-making framework.18 In June2024, the CDC updated its guidelines to recommend a single, routine dose of RSV vaccine for all adults aged 75 and older, as well as those aged 60–74 who are at increased risk for severe RSV illness.19 Most recently, in 2025, the CDC expanded the risk-based recommendation to include those 50–59 y of age.20 Less than a quarter of beneficiaries enrolled in the Medicare fee-for-service program were vaccinated during the first RSV vaccination season, from July 1, 2023 to June 30, 2024.21 There are limited data on RSV vaccine uptake among enrollees in Medicare Advantage (MA) plans, which comprise approximately half of the US population aged ≥65 years. The aim of this study was to examine monthly trends in RSV vaccine uptake among older adults enrolled in a large national MA health plan across two respiratory disease seasons, 2023/2024 and the first half of the 2024/2025 season. Materials and methods We conducted a retrospective observational analysis using the Humana Research Database. Humana is the second‑largest private Medicare insurer in the US, with more than 6.2 million MA enrollees as of December 31, 2024. The Humana Research Database contains healthcare administrative claims data, enrollment data—including demographics, medical, and pharmacy claims with information on service dates, place of service, diagnosis and CPT/HCPCS codes, and treatments, including RSV vaccines and other immunizations received by enrollees. We examined enrollment, pharmacy, and medical claims data for adults aged ≥65 years during the study period of July 1, 2022–December 31, 2024. The date of RSV vaccine administration during the identification period (July 1, 2023–December 31, 2024) was regarded as the index date. A 12-month baseline period (including the month of RSV vaccine administration) was used for identifying conditions considered by the CDC as high-risk for severe RSV illness.18 Continuous enrollment during the baseline period was required for inclusion in the study. All available data back to July 1, 2023 were used for assessing vaccination history. Individuals were excluded from the study if they had two or more claims for RSV vaccine administration during the study period. National Drug Codes (NDCs) and Healthcare Common Procedure Coding System (HCPCS) codes were used to identify RSV vaccine administration among enrollees, and the number of beneficiaries vaccinated for RSV per 10,000 beneficiaries was calculated for each calendar month. The denominator for each month included the beneficiaries with continuous enrollment during the calendar month of analysis and the 11 calendar months before that, but excluded all individuals with prior evidence of RSV vaccination using all available data back to July 1, 2023. Only N = 1 administration of RSV vaccination was observed during July 2023; therefore, vaccination rates are reported for August 2023 and onward. For the September–December months, unadjusted incidence rate ratio (IRR) and 95% confidence interval (CI) were calculated to assess the change in RSV vaccine uptake from 2023 to 2024 for each of these months. The IRR was calculated by dividing the vaccination rate observed during the given month in 2024 by the vaccination rate in the same month in 2023. CIs were calculated using the approximate method. Vaccine administration rate results were stratified by age groups (65–74 years and ≥75 years) and by presence or absence of high-risk conditions for severe RSV identified by the CDC.19 To identify the RSV vaccine‑eligible enrollees who remained unvaccinated for RSV on December 31, 2024, all MA plan enrollees continuously enrolled between July 2023 and December 2024 were first identified, and the proportion of individuals who met the 2024 CDC recommendations for RSV vaccination but has no evidence of RSV vaccine as of December 31, 2024 was reported. This study was approved by Humana’s Human Subject Protection Office prior to study initiation. Results RSV vaccine uptake increased from August 2023 (46 per 10,000) and peaked during October 2023 (310 per 10,000, Figure 1). The uptake declined to 208 per 10,000 in December 2023 and was lower from January 2024 (143 per 10,000) until June 2024 (29 per 10,000). At the beginning of the 2024/2025 season in July 2024, the uptake of RSV vaccines was 27 per 10,000 and peaked in October 2024 (137 per 10,000). Similar to the 2023 time frame, RSV vaccine uptake declined from October to December 2024 (69 per 10,000). The IRR (95% CI) for the September –December months in 2023 and 2024 ranged from 0.330 (0.325, 0.335) to 0.441 (0.436, 0.446). Monthly RSV vaccine uptake overall, stratified by age group, and relative difference in vaccine uptake by age group. Note: The primary vertical axis corresponds to vaccination rates per 10,000 members, as reflected in the bar chart. The secondary vertical axis corresponds to the relative difference in vaccination for the age groups, as reflected in the line plot. Data for July 2023 were not reported, as only N = 1 administration of the RSV vaccine was observed during that time frame. The mean age of RSV vaccine recipients was approximately 75 years, with females representing a higher proportion of the recipients (57.9%). While the majority of individuals vaccinated during the study period were classified as White (76.9%), the proportion of vaccine recipients classified as Black increased (10.9% between July 2023 and December 2023; 15.2% between July 2024 and December 2024). Overall vaccine uptake was higher among individuals age ≥75 years compared to those aged 65–74 years. During August 2023–December 2023, the monthly relative difference between these two age groups ranged from 2.8 % to 18.9% (Figure 1). The relative vaccination difference (vaccination rate for age ≥75 years/vaccination rate for 65–74 years) increased substantially after the release of the 2024 CDC recommendations, reflecting greater uptake among older individuals with an age-based recommendation for those 75 and older, ranging from 62.2% to 84.4% during July–December 2024. Detailed rates per month and relative differences are available in Supplementary Table 1. After the CDC recommendations were updated in June 2024, the relative difference in RSV vaccine uptake among adults aged 65–74 years with risk factors for severe RSV compared to those without risk factors was greater than in 2023 (Figure 2). Monthly RSV vaccine uptake for individuals age 65–74 years, stratified by risk group, and relative difference in vaccine uptake by risk group. Note: The primary vertical axis corresponds to vaccination rates per 10,000 members, as reflected in the bar chart. The secondary vertical axis corresponds to the relative difference in vaccination for risk groups, as reflected in the line plot. Data for July 2023 were not reported, as only N = 1 administration of the RSV vaccine was observed during that time frame. From July through December 2024, the relative difference in vaccination was highest (range 99.2%–125.5%) among the younger segment of the population (65–74 years). Among the older age group (≥75 years), the monthly relative difference in vaccination for high-risk individuals and those without risk factors had a narrower range over the study period (21.5%–90.4%) (Figure 3). Monthly RSV vaccine uptake for individuals age ≥75 years, stratified by risk group, and relative difference in vaccine uptake by risk group. Note: The primary vertical axis corresponds to vaccination rates per 10,000 members, as reflected in the bar chart. The secondary vertical axis corresponds to the relative difference in vaccination for risk groups, as reflected in the line plot. Data for July 2023 were not reported, as only N = 1 administration of the RSV vaccine was observed during that time frame. As of 31 December 2024, among approximately 1.7 MM individuals who met the 2024 CDC recommendations for RSV vaccination and were continuously enrolled during the period of vaccine availability, slightly over 80% did not have evidence of RSV vaccination. A vast majority (82.9%) of these RSV unvaccinated members had one or more high-risk conditions for severe RSV illness. Discussion The 2023 CDC guidelines recommended RSV vaccine administration for all adults 60 years and older using shared clinical decision-making.18 Findings from the current analysis suggest that even under this initial set of broad guidelines, vaccine uptake was highest among those aged ≥75 years and among those with the conditions that put them at high risk for RSV, without regard to age. After changes to the CDC recommendations in 2024 to explicitly reflect age-and-risk-based routine recommendations (age ≥75 years and age 60–74 years with risk factors), relative trends in terms of vaccine uptake among older vs. younger adults and with vs. without risk factors for severe RSV illness were directionally similar; however, the relative difference in vaccine uptake widened for older individuals and those with high-risk conditions for severe RSV.7 RSV vaccine uptake during the second half of 2024 was markedly lower than the same time frame in 2023. Between September and December 2024, 56%–67% fewer patients received the RSV vaccine compared with the same period in 2023. The lower uptake in the second season (2024/2025) could be a result of multiple factors. These include the possibility that most of the early adopters of RSV vaccination received the vaccine in the 2023/2024 season. Additionally, the 2024 CDC recommendations narrowed the eligible population by excluding individuals aged 60–74 years who did not have risk conditions for severe RSV illness. Another potential reason could be vaccine fatigue – when individuals become indifferent to vaccine information or guidance because they feel overwhelmed or burned out.22,23 Vaccine fatigue has become prevalent in the US after the COVID-19 pandemic, as more vaccines are now recommended for the adult population. However, there is a lack of available literature on vaccine fatigue specific to RSV vaccines in the context of all other vaccines that are recommended for older adults. Another plausible reason could be a missed opportunity to vaccinate for RSV during a healthcare encounter.24 One of the reasons for the missed opportunity could be related to larger system issues, e.g., RSV vaccine is covered by Medicare Part D, while doctor visits are covered by Medicare Part A or Part B. This could add an administrative barrier to RSV vaccine administration at a doctor’s clinic, leading to low RSV vaccine administration at clinics. A plausible reason for low uptake could also be that eligible adults may have a low perception of vulnerability or RSV disease awareness. It is to be noted that RSV vaccines are available at the majority of retail pharmacies within the USA and cost $0 to patients enrolled in MA plans. During the study period, there were no known RSV vaccine supply issues or any policy changes that would have impacted access to these vaccines. Other studies have reported RSV vaccine uptake, including a study by Murphy et al. that found, among the Medicare fee-for-service beneficiaries, only 21.0% received the RSV vaccine in the first season (defined as July 2023–June 2024), with the highest uptake among the 75–84 age group (23.6%) and those with at least one comorbidity (21.8%).21 Additionally, La et al. reported that in the IQVIA database of nearly 78 million US adults aged ≥60 years, only 16.4% received RSV vaccination between August 2023 and February 2025.25 Similarly, Hye SK et al. analyzed the Veterans Affairs Corporate Data and reported that only 9.8% of veterans received the RSV vaccine in the 2023–2024 season, and an additional 2.7% of veterans after 4 months of the 2024–2025 season.26 This low uptake in general suggests that strong outreach campaigns may be needed to support vaccination education for patients and providers and to manage barriers for patients, particularly among those with high-risk conditions for severe RSV illness. To our knowledge, this is among the first studies to provide insights on RSV vaccine uptake trends among MA plan enrollees in the United States during this time period. Strengths of this study include utilizing the Humana claims database. Humana is the second‑largest MA plan, with membership representing approximately 20% of all MA enrollees in the United States. Additionally, during the study time frame, RSV vaccination was covered by the health plan with $0 member out-of-pocket cost, thus promoting comprehensive capture of RSV vaccine administration in the database. Our study has limitations. First, the population was restricted to individuals 65 y and older. CDC recommendations during the 2023 and 2024 time frame included individuals 60 y and older. Individuals enrolled in MA and under the age of 65 typically qualify for benefits due to disability or unique factors. These individuals were excluded from the analysis because they are not generally representative of that particular age group (≥65 y), and vaccination uptake trends may be meaningfully different from the general population. Second, at the time this study was conducted, only data through the end of 2024 were available, limiting the ability to assess trends for the entire 2024/2025 season. However, a majority of the uptake of respiratory vaccines, including RSV, occurs during the first few months of the season, providing reasonable assurance of capturing the bulk of vaccine uptake for the season.21,27 Since this study used claims data for identifying RSV vaccine uptake, cases where the RSV vaccine could have been administered without filing a claim could not be captured. Conclusion We found the RSV vaccination to be low overall in this MA population, but particularly lower in the 2024/2025 RSV season compared with the 2023/2024 RSV season. RSV vaccination was higher among adults ≥75 years than those 65–74 years old and among those with high-risk conditions for severe RSV illness than those without the high-risk conditions. Even before the update in CDC recommendations from shared clinical decision making to age-and-risk-based routine recommendations, most individuals receiving the RSV vaccine had a high-risk condition for severe RSV. Our study highlights these trends in RSV vaccine uptake and the substantial number of older individuals who may be at risk for severe RSV illness but remain unvaccinated. This study emphasizes the need to better understand vaccination dynamics, patient health beliefs and behaviors, system challenges to vaccine access, and opportunities to increase RSV vaccine uptake among Medicare beneficiaries. Supplementary Material Supplemental Material Acknowledgments Medical writing support was provided by Dr Mary Costantino, PhD, at Humana Healthcare Research, Inc., and was funded by Pfizer. Biography Vishal Saundankar, B. Pharm., MS, is Research Consulting Lead with Humana Healthcare Research, Inc. (HHR), specializing in retrospective database analysis, comparative effectiveness, and health outcomes research. He has published in journals such as Journal of Managed Care and Specialty Pharmacy, BMJ Open Diabetes Research & Care, Population Health Management, BMC Geriatrics, Advances in Therapy, American Journal of Managed Care, Annals of American Thoracic Society, Journal of Oncology Practice, Clinical Breast Cancer, and Drugs Real World Outcomes. Mr. Saundankar has served as an analyst for the US FDA’s post‑licensure Rapid Immunization Safety Monitoring studies. His contribution to research work has been acknowledged in articles published in journals like Pediatrics and The American Journal of Pharmacy Benefits. Earlier, he worked as a biostatistician for 3 y, focusing on healthcare outcomes and pharmacy care management. Prior to moving to the United States, he was a registered pharmacist in India and worked in the pharmaceutical industry for 6 y in therapeutic areas including infertility, hepatology, central nervous system, and gastrointestinal diseases. He is also a reviewer for prominent journals. Mr. Saundankar holds an MS in pharmacy administration from the University of Houston and a BS in pharmacy from the University of Pune, India. Funding Statement This study was sponsored by Pfizer Inc. The study sponsor, Pfizer Inc., reviewed the study research plan and study manuscript; data management, processing, and analyses were conducted by Humana Healthcare Research, Inc. All final analytic decisions and the decision to submit for publication were made solely by the study investigators. Disclosure statement RS, RM, PS, KF, and EWC are employees of Pfizer Inc. and hold Pfizer stock. VS, CB, RS, and BS are employees of Humana Healthcare Research, Inc., which received funding from Pfizer Inc. in connection with the development of this manuscript and this study. The authors report no other relevant conflicts of interest. Data availability statement Due to legal and privacy restrictions, the underlying patient-level analytical file is not available for public access. Ethics approval and consent to participate This study was conducted using coded healthcare insurance claims data. Prior to execution, the study was submitted to Humana’s Human Subject Protection Office determination process. Using the US Department of Health and Human Services regulations found at 45 CFR 46 and the Office of Human Research Protections Guidance on Coded Private Information or Specimens Use in Research (2008), this research project was classified as Not Human Subjects Research. (Reference: eCFR : 45 CFR 46.104– Exempt research. Coded Private Information or Specimens Use in Research, Guidance (2008) | HHS.gov). Supplementary material Supplemental data for this article can be accessed online at https://doi.org/10.1080/21645515.2026.2745402 References Associated Data Supplementary Materials Supplemental Material Data Availability Statement Due to legal and privacy restrictions, the underlying patient-level analytical file is not available for public access.